News
July 2026
EarlyDiagnostics announced the publication of the clinical validation results of its proprietary MethylScan™ platform for hepatocellular carcinoma (HCC) surveillance in Hepatology Communications. The study, titled "Methylation Plus Alpha-Fetoprotein Blood Test for Early Detection of HCC in At-Risk Populations," demonstrated that MethylScan™ HCC achieved 73% sensitivity at 92% specificity for detecting early-stage HCC (within Milan criteria).
[Hepatology Communications]
May 2026
EarlyDiagnostics (EarlyDx) announced that its proprietary MethylScan™ platform has been validated in a peer-reviewed study published in the Proceedings of the National Academy of Sciences (PNAS). The study demonstrated that MethylScan™ can detect multiple cancers, liver diseases, and organ abnormalities from a single blood sample.
[NBC News] [BusinessWire] [U.S. News & World Report]
April 2026
EarlyDx is exhibiting at AACR 2026. We welcome opportunities to discuss collaborations and strategic partnerships.
April 2026
Fraud Alert: EarlyDx has been alerted to fraudulent recruiting emails impersonating our company. Our official domain is earlydx.com. We do not authorize emails from other domains. Do not send personal information in response. Please verify any recruiting communication through our official website. [LinkedIn]
November 2025
We’re proud to share new data presented at AASLD’s The Liver Meeting® 2025 showcasing the power of EarlyDx’s methylation-based liquid biopsy platform for early hepatocellular carcinoma (HCC) detection. In a late-breaking oral presentation, Dr. Neehar Parikh presented validation results from a blood-based assay combining DNA methylation and AFP for HCC surveillance. [LinkedIn]
October 2025
Congratulations to our laboratory team! EarlyDx has received accreditation from the College of American Pathologists (CAP), the most exacting in laboratory science.
Download the certificate: [CAP#: 9954593]
April 2025
EarlyDx has been granted a CPT® Proprietary Laboratory Analysis (PLA) code for MethylScan™ HCC by the American Medical Association (AMA), published on April 1, 2025.
December 2024
EarlyDx is certified under the Clinical Laboratory Improvement Amendments (CLIA) and California State.
Download copies of licenses: [CLIA-Certificate]
[State of California License]
October 2024
EarlyDx Co-founder Jasmine Zhou received an Eminent Scholar Award from the International Association for Intelligent Biology and Medicine, in recognition of her outstanding research innovation.
October 2023
In collaboration with UCLA and MD Anderson, EarlyDx has been awarded a NIH U01 grant on "Multi-cancer early detection using cell-free DNA methylome analysis". With this award, EarlyDx will join the NIH Liquid Biopsy Consortium.
September 2023
EarlyDx has been awarded a NIH SBIR Phase II contract on building a cloud-based Liquid-biopsy and Radiomics Platform for early cancer detection.
July 2023
EarlyDx published Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring.
Proc Natl Acad Sci USA. 2023 Jul;120(28):e2305236120.
News highlight by UCLA news, The Medical News, Drug Target Review, Medical Xpress, and Healthcare in Europe.
Check media coverage summary.
September 2022
Our technology on using cfDNA methylome to detect cancer has been published in Nature Communications.
It has been recognized as one of the "Top 25 Health Sciences Articles of 2022" by Nature Communications.
News link:
[UCLA News]
[GenomeWeb]
[HemOnc Today]
[ScieneDaily]
[Biocompare]
September 2022
EarlyDx has been awarded a NIH SBIR Phase II grant on validating our cfDNA methylome technology for the early detection of liver and lung cancer.